Redx Pharma plc Redx notes election of Lisa Anson to UK BIA BOD
29 October 2018 - 6:00PM
RNS Non-Regulatory
TIDMREDX
Redx Pharma plc
29 October 2018
REDX PHARMA PLC
("Redx" or "the Company")
REDX Pharma notes election of Lisa Anson to UK BIA Board of
Directors
Alderley Park, 29 October 2018 Redx (AIM: REDX), the drug
development company focused on cancer and fibrosis, notes the
announcement from the UK BioIndustry Association ("BIA") that Lisa
Anson, CEO of the Company, has been elected to serve on the BIA
Board of Directors. Her tenure will commence on January 1(st) 2019
and is for a three year term.
Lisa Anson, CEO of REDX pharma Plc, commented: "I am delighted
to be elected to join the BIA Board. I am passionate about the UK
Biotech sector, as it is not only the focus for much of the
exciting science in the UK, but it is also an important sector
supporting the UK economy. Having previously been President of the
Association of the British Pharmaceutical Industry (ABPI), I am
personally excited at the prospect of working with the BIA to
further the Industry."
The full text of the BIA press release appears below
For further information, please contact:
Redx Pharma Plc T: +44 1625 469
920
Lisa Anson, Chief Executive Officer
Cantor Fitzgerald Europe (Nominated Advisor & T: +44 20 7894
Broker) 7000
Phil Davies
WG Partners LLP (Joint Broker) T: +44 20 3705
9330
Claes Spång/ Chris Lee/ David Wilson
FTI Consulting T: +44 20 3727
1000
Simon Conway/Stephanie Cuthbert
About Redx Pharma Plc
Redx is a UK biotechnology company whose shares are traded on
AIM (AIM:REDX). Redx's vision is to become a leading biotech
focused on the development of novel precision medicines that have
the potential to transform treatment in oncology and fibrotic
diseases.
If you would like to sign up to regular alerts from Redx Pharma,
please follow this link
https://www.redxpharma.com/investors/email-alerts/.
The full text of the announcement from the BIA:
BIA announces new appointments to the BIA Board at 2018 AGM
26 OCT 18- Following the BIA AGM last week, the Association has
announced the new members who have been elected to its Board of
Directors. The AGM took place on Thursday 18(th) October at the
QEII Centre as part of the BIA's annual UK Bioscience Forum and the
new board members were voted for by the BIA's membership in the
weeks leading up to the meeting.
There were four corporate places and one 'other' member place to
fill at the election and the new Board members who will join the
Board from January 1(st) 2019 for a three year term are:
Corporate Board Members:
-- Lisa Anson of Redx Pharma
-- Charlotte Casebourne of Theolytics
-- Oliver Hardick of Puridify
-- Andrew Hotchkiss of Immunocore
Other Board Member:
-- Clare Terlouw of Syncona
BIA CEO Steve Bates said: "These new appointments, emphasise the
diversity of the membership we represent. They build on the current
strength of the BIA Board and broaden our expertise as the
Association continues to take on the challenges presented by Brexit
to ensure that our members can grow and be successful."
Chair of the BIA Board, Dr Jane Osbourn said: "We had an
outstanding and comprehensive range of candidates stand for
election this year and I would encourage all of those who were not
successful this time around to look at standing next year. The BIA
Board does an excellent job of representing the membership and
leading the Association's work and I look forward to working with
the new Directors over the coming year."
For more information on the BIA Board - go to the about us
section on the BIA website
https://www.bioindustry.org/about-us.html
Ends
Contact:
Ed Sexton, BIA Communications and Media Relations Manager -
esexton@bioindustry.org 0207 630 2196
About the UK BioIndustry Association (BIA)
Established over 25 years ago at the infancy of biotechnology,
the BioIndustry Association (BIA) is the trade association for
innovative enterprises involved in UK bioscience. Members include
emerging and more established bioscience companies; pharmaceutical
companies; academic, research and philanthropic organisations; and
service providers to the bioscience sector. The BIA represents the
interests of its members to a broad section of stakeholders, from
government and regulators to patient groups and the media. Our goal
is to secure the UK's position as a global hub and as the best
location for innovative research and commercialisation, enabling
our world-leading research base to deliver healthcare solutions
that can truly make a difference to people's lives.
For further information, please go to www.bioindustry.org and
twitter.com/BIA_UK
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAFKFDKBBDBOKB
(END) Dow Jones Newswires
October 29, 2018 03:00 ET (07:00 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024